Birth Defects with the Use of Valproate: An  Impact on the Prescribing Pattern amongst  the Health Care Professionals in India

Dr V KALAISELVAN; Dr NISHITH KESERWANI; Dr RISHI KUMAR; Dr RAJEEV SINGH RAGHUVANSHI; Dr KRISHNAMURTHY B

doi:10.59793/ijcp.v35i1.1030

Authors

Dr V KALAISELVAN Senior Principal Scientific Officer
Dr NISHITH KESERWANI Junior Pharmacovigilance Associate
Dr RISHI KUMAR Ex-Scientific Assistant
Dr RAJEEV SINGH RAGHUVANSHI Secretary-cum-Scientific Director Indian Pharmacopoeia Commission, National Coordination Centre, Pharmacovigilance
Dr KRISHNAMURTHY B Assistant Professor, Dept. of Clinical Pharmacology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India

DOI:

https://doi.org/10.59793/ijcp.v35i1.1030

Keywords:

Sodium valproate, valproic acid,, pharmacovigilance,, AMCs,, health care professionals

Abstract

Objective: The present study was carried out to evaluate the impact of Pharmacovigilance Programme of India (PvPI) initiative
to reduce the use of sodium valproate/valproic acid (SV/VA) in the women of childbearing age group. Methods: In our
questionnaire-based study, 251 health care professionals (HCPs) participated from 41 medical colleges across India, which are
also working as Adverse drug reaction Monitoring Centres (AMCs) under PvPI. Results: The data collected at the National
Coordination Centre (NCC) shows the significant decrease in the use of SV/VA in the women of childbearing age group after
the PvPI initiative on Information, Education, and Communication (IEC) materials for HCPs. However, it was found that
40% of HCPs of Gynecology and Neurology Department were still not aware of the initiative taken by the Government of
India to reduce the use of SV/VA in the women of childbearing age group. Conclusion: PvPI, therefore, needs to take more
measures to increase the reach of their resource materials to all HCPs.